Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
about
Long-acting atypical antipsychotics: characterization of the local tissue responseEfficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparisonA 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendationClinical pharmacology of atypical antipsychotics: an update.A review of olanzapine pamoate.Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.A review of paliperidone palmitate.Drug safety evaluation of olanzapine pamoate.Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection.Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being.Preparation, Characterization, and In Vivo Evaluation of Olanzapine Poly(D,L-lactide-co-glycolide) Microspheres.Olanzapine long-acting injection: When and for how long is oral supplementation required?Understanding depot antipsychotics: an illustrated guide to kinetics.
P2860
Q34130433-6A1E3931-6524-4A9F-BAB0-87C7E3B15354Q34286350-236A9DE5-EFB2-4613-9AF6-16E84FEDC58CQ34293855-20729A03-BCA1-4B11-AF46-847BD7A8E2E2Q34720828-20C7F6C3-537E-4812-B337-DD141FFD004BQ35683860-DF008D8E-6B7B-4E29-81D4-33CAB6B394D6Q35728228-1CCE621C-9EC3-4572-BFBB-5A3E705315D2Q38022638-88C405E5-502A-49FE-AB85-E515A9A6F1F7Q38042478-73E045D4-5B0A-466C-BA34-74F99D33A915Q38067137-B5AEC09C-FAE1-4D41-8D7D-F84048836BCAQ38136262-79C932B7-C8C4-495C-8460-78A81D58ADD5Q38248274-51CE7A69-934B-4B21-8554-2F3B70B6338BQ38271353-26D7BAED-AACF-4A80-9FC7-00944B2FBE99Q38694855-33483ADA-91BC-4E93-8C6A-CB09C7FA796DQ39207081-6FDBE456-6C6F-4AFF-A01A-FB23CD83C6D5Q40335811-FFFFBBAF-18DD-44F3-8420-0CDFE23BC02BQ44973469-BDC4CC43-3DDB-47DD-9FC4-5E0AB982E09DQ45769368-4705B2A2-3B89-4446-A548-65C5F6E895EF
P2860
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
@en
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
@nl
type
label
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
@en
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
@nl
prefLabel
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
@en
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
@nl
P2860
P1433
P1476
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
@en
P2093
James E Frampton
P2860
P304
P356
10.2165/11204930-000000000-00000
P577
2010-12-01T00:00:00Z
P6179
1035633881